Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma
BackgroundSystemic chemotherapy has been the mainstay treatment for locally advanced or metastatic urothelial carcinoma (UC). In the past few years, novel immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have improved the treatment of advanced UC.Case presentationHere, we repo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.978266/full |
| _version_ | 1798018584433131520 |
|---|---|
| author | Zhenying Xu Jiaman Ma Ting Chen Yu Yang |
| author_facet | Zhenying Xu Jiaman Ma Ting Chen Yu Yang |
| author_sort | Zhenying Xu |
| collection | DOAJ |
| description | BackgroundSystemic chemotherapy has been the mainstay treatment for locally advanced or metastatic urothelial carcinoma (UC). In the past few years, novel immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have improved the treatment of advanced UC.Case presentationHere, we report systemic therapy of a 68-year-old male diagnosed with HER2 positive (immunohistochemistry 3+), programmed cell death ligand 1(PD-L1) negative metastatic UC, and renal insufficiency. He had encountered numerous metastases and failed first-line platinum-based chemotherapy and second-line treatment with pembrolizumab and trastuzumab. During third-line treatment with RC48 (a HER2 targeting ADC) combined with pembrolizumab, he achieved a rapid partial response (PR) in the first evaluation and subsequent complete response (CR) on PET/CT and long-term progression-free survival (>12 months) at the last follow-up on 25 August 2022. There are no grade 3 or 4 adverse events or aggravations of renal insufficiency during the third-line therapy.DiscussionRC48 combined with pembrolizumab demonstrated outstanding efficacy and safety in this HER2-positive metastatic UC patient. ADC combined with ICI is a promising anti-tumor strategy that deserves further exploration in advanced UC. |
| first_indexed | 2024-04-11T16:26:30Z |
| format | Article |
| id | doaj.art-271ab7709e954ad1a3d9119d0f4fdde2 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T16:26:30Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-271ab7709e954ad1a3d9119d0f4fdde22022-12-22T04:14:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-11-011310.3389/fimmu.2022.978266978266Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinomaZhenying XuJiaman MaTing ChenYu YangBackgroundSystemic chemotherapy has been the mainstay treatment for locally advanced or metastatic urothelial carcinoma (UC). In the past few years, novel immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have improved the treatment of advanced UC.Case presentationHere, we report systemic therapy of a 68-year-old male diagnosed with HER2 positive (immunohistochemistry 3+), programmed cell death ligand 1(PD-L1) negative metastatic UC, and renal insufficiency. He had encountered numerous metastases and failed first-line platinum-based chemotherapy and second-line treatment with pembrolizumab and trastuzumab. During third-line treatment with RC48 (a HER2 targeting ADC) combined with pembrolizumab, he achieved a rapid partial response (PR) in the first evaluation and subsequent complete response (CR) on PET/CT and long-term progression-free survival (>12 months) at the last follow-up on 25 August 2022. There are no grade 3 or 4 adverse events or aggravations of renal insufficiency during the third-line therapy.DiscussionRC48 combined with pembrolizumab demonstrated outstanding efficacy and safety in this HER2-positive metastatic UC patient. ADC combined with ICI is a promising anti-tumor strategy that deserves further exploration in advanced UC.https://www.frontiersin.org/articles/10.3389/fimmu.2022.978266/fullurothelial carcinomahuman epidermal growth factor receptor 2 (HER2),trastuzumab (herceptin)pembrolizumabantibody-drug conjugatesRC48-ADC |
| spellingShingle | Zhenying Xu Jiaman Ma Ting Chen Yu Yang Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma Frontiers in Immunology urothelial carcinoma human epidermal growth factor receptor 2 (HER2),trastuzumab (herceptin) pembrolizumab antibody-drug conjugates RC48-ADC |
| title | Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma |
| title_full | Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma |
| title_fullStr | Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma |
| title_full_unstemmed | Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma |
| title_short | Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma |
| title_sort | case report the remarkable response of pembrolizumab combined with rc48 in the third line treatment of metastatic urothelial carcinoma |
| topic | urothelial carcinoma human epidermal growth factor receptor 2 (HER2),trastuzumab (herceptin) pembrolizumab antibody-drug conjugates RC48-ADC |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.978266/full |
| work_keys_str_mv | AT zhenyingxu casereporttheremarkableresponseofpembrolizumabcombinedwithrc48inthethirdlinetreatmentofmetastaticurothelialcarcinoma AT jiamanma casereporttheremarkableresponseofpembrolizumabcombinedwithrc48inthethirdlinetreatmentofmetastaticurothelialcarcinoma AT tingchen casereporttheremarkableresponseofpembrolizumabcombinedwithrc48inthethirdlinetreatmentofmetastaticurothelialcarcinoma AT yuyang casereporttheremarkableresponseofpembrolizumabcombinedwithrc48inthethirdlinetreatmentofmetastaticurothelialcarcinoma |